Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Public ClinicalTrials.gov record NCT00440726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) for treating adults with multiple myeloma which is a type of blood cancer. Bortezomib has been shown to cause cancer cells to die in studies done on animals (mice). Studies have been done that have shown that some adults and children with cancer have shown a response to bortezomib when it is used alone. Studies have also been done in adults to evaluate the dose of bortezomib that can be safely given in combination with other chemotherapy drugs.
Study identification
- NCT ID
- NCT00440726
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 31 participants
Conditions and interventions
Conditions
Interventions
- Bortezomib Drug
- Dexamethasone Drug
- PEG-asparaginase Drug
- Doxorubicin Drug
- Cytarabine Drug
- Methotrexate Drug
- Vincristine Drug
- Triple IT Therapy Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Year to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 3, 2006
- Primary completion
- Feb 25, 2011
- Completion
- Feb 25, 2011
- Last update posted
- Feb 18, 2020
2006 – 2011
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | — |
| Miller Children's Hospital | Long Beach | California | 90806 | — |
| Childrens Hospital Los Angeles | Los Angeles | California | 90027 | — |
| Children's Hospital & Research Center Oakland | Oakland | California | 94618 | — |
| Stanford University Medical Center | Palo Alto | California | 94304-1812 | — |
| UCSF School of Medicine | San Francisco | California | 94143-0106 | — |
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010 | — |
| University of Miami Cancer Center | Miami | Florida | 33136 | — |
| Children's Healthcare of Atlanta | Atlanta | Georgia | 30322 | — |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611 | — |
| Johns Hopkins / Sydney Kimmel Cancer Center | Baltimore | Maryland | 21231 | — |
| Dana Farber Cancer Center | Boston | Massachusetts | 02215 | — |
| C.S. Mott Children's Hospital | Ann Arbor | Michigan | 48109-0914 | — |
| Childrens Hospital & Clinics of Minnesota | Minneapolis | Minnesota | 55404-4597 | — |
| New York University Medical Center | New York | New York | 10016 | — |
| Children's Hospital New York-Presbyterian | New York | New York | 10032 | — |
| Levine Children's Hospital | Charlotte | North Carolina | 28203 | — |
| Nationwide Children's Hospital | Columbus | Ohio | 43205 | — |
| Primary Children's Hospital | Salt Lake City | Utah | 84113 | — |
| Seattle Children's Hospital | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00440726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 18, 2020 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00440726 live on ClinicalTrials.gov.